期刊文献+

Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pylori 被引量:5

下载PDF
导出
摘要 BACKGROUND The resistance rate to antibacterial drugs is the key inhibitor of Helicobacter pylori(H.pylori)eradication treatment.AIM To evaluate the prevalence and drug resistance of H.pylori based on big data.METHODS Gastric mucosal specimens were collected from naive patients undergoing upper gastrointestinal endoscopy for H.pylori culture and antimicrobial susceptibility testing(AST),including clarithromycin,levofloxacin,metronidazole and amoxicillin.Every 10 years of age was grouped as an age group.The H.pylori infection and resistance were explored based on the age group and gender.RESULTS The number of H.pylori-positive specimen was 94509 in 283823 gastric mucosal specimens,with an infection rate of 33.30%.The infection rate increased with age,and males had a higher infection rate than females.The average resistance rate of H.pylori to amoxicillin and metronidazole was 0.21%and 93.72%,which remained stable.The average resistance rate to clarithromycin was 23.99%with an increasing trend from 14.43%to 38.24%.The average resistance rate to levofloxacin was 30.29%,which increased from 17.07%to 39.42%and mostly stabilized after 2017.The resistance rate of H.pylori increased with age,except amoxicillin.H.pylori in females are at higher risk of resistance to metronidazole but not to amoxicillin,regardless of the age group.Meanwhile,H.pylori in females are at higher risk of resistance to levofloxacin and clarithromycin in the 21-50 age group.The single,dual,triple and quadruple-drug resistance rate was 54.59%,29.03%,11.71%and 0.11%,respectively.CONCLUSION The resistance of H.pylori in Taizhou city is serious.Guided by the consensus report,individualized treatment based on AST is recommended.
出处 《World Journal of Clinical Cases》 SCIE 2021年第35期10838-10849,共12页 世界临床病例杂志
基金 Taizhou Science and Technology Plan Project,No.1701KY20.
  • 相关文献

参考文献3

二级参考文献35

共引文献22

同被引文献47

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部